Veracyte Company Profile (NASDAQ:VCYT)

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Veracyte, Inc. (NASDAQ:VCYT) issued its earnings results on Monday, July, 31st. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.25) by $0.03. The company had revenue of $18.40 million for the quarter, compared to analysts' expectations of $18.32 million. Veracyte had a negative net margin of 35.64% and a negative return on equity of 53.58%. Veracyte's quarterly revenue was up 25.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.40) EPS. View Veracyte's Earnings History.

Veracyte is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Veracyte.

6 analysts have issued 12 month target prices for Veracyte's stock. Their predictions range from $12.00 to $15.00. On average, they anticipate Veracyte's share price to reach $13.25 in the next year. View Analyst Ratings for Veracyte.

Here are some recent quotes from research analysts about Veracyte stock:

• 1. According to Zacks Investment Research, "Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also developing Afirma Malignant GEC test. It serves endocrinologists, radiologists, and head and neck specialists. Veracyte, Inc. is headquartered in South San Francisco, California. " (8/4/2017)
• 2. Leerink Swann analysts commented, "We reiterate our OP rating and maintain our PT of $12. Commercial Payers Still Key to Driving Adoption Ramp and Sales Longer-term. VCYT has successfully driven the Afirma adoption ramp by gaining multi-year commercial payer contracts on the back of solid clinical evidence — as 80% of Afirma volumes still comes from private payers. Afirma currently has 185M lives covered and $155M contracted with 25M of those lives in Blue Cross Blue Shield. Beyond that, for Afirma GEC, VCYT’s key priorities include securing a positive coverage decision for the largest Blues payer: Anthem (ANTM, OP) with its 40M covered lives, and converting other Blues payers to in-network contracts. Medicare accounts for only 20% of Afirma test samples and thus the eliminated impact was only ~$1.6M. Plus, with the new data that was released at the ATA meeting recently highlighting 70%-80% of specificity of the enhanced Afirma test, we believe VCYT should be able to get Anthem as well." (11/22/2016)

Some companies that are related to Veracyte include Triple-S Management Corporation (GTS), Assembly Biosciences (ASMB), Calithera Biosciences (CALA), Achillion Pharmaceuticals (ACHN), Inovio Pharmaceuticals (INO), Sucampo Pharmaceuticals (SCMP), Celyad SA (CYAD), Kindred Healthcare (KND), Tactile Systems Technology (TCMD), Clementia Pharmaceuticals (CMTA), Mesa Laboratories (MLAB), Invacare Corporation (IVC), RadNet (RDNT), GenMark Diagnostics (GNMK), Aurinia Pharmaceuticals (AUPH), Kala Pharmaceuticals (KALA), Karyopharm Therapeutics (KPTI) and Progenics Pharmaceuticals (PGNX).

Veracyte's management team includes the folowing people:

• Bonnie H. Anderson, Chairman of the Board, Chief Executive Officer
• Christopher M. Hall, President, Chief Operating Officer
• Keith S. Kennedy, Chief Financial Officer
• Julie A. Brooks, General Counsel, Secretary
• John W. Hanna, Chief Commercial Officer
• John L. Bishop, Lead Independent Director
• Fred E. Cohen Ph.D. M.D., Independent Director
• Karin Eastham CPA, Independent Director
• Robert S. Epstein M.D., Independent Director
• Kevin K. Gordon, Independent Director

Veracyte's stock is owned by a variety of of retail and institutional investors. Top institutional investors include TPG Group Holdings SBS Advisors Inc. (10.48%), Broadfin Capital LLC (4.27%), Vanguard Group Inc. (2.63%), Stonepine Capital Management LLC (2.55%), First Light Asset Management LLC (2.23%) and Federated Investors Inc. PA (1.55%). Company insiders that own Veracyte stock include Bonnie H Anderson, Evan/ Fa Jones and Jesse I Treu. View Institutional Ownership Trends for Veracyte.

Veracyte's stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, EAM Investors LLC, Parametric Portfolio Associates LLC, Grandeur Peak Global Advisors LLC, OxFORD Asset Management LLP, Russell Investments Group Ltd. and Boston Advisors LLC. Company insiders that have sold Veracyte stock in the last year include Bonnie H Anderson, Evan/ Fa Jones and Jesse I Treu. View Insider Buying and Selling for Veracyte.

Veracyte's stock was acquired by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, ARK Investment Management LLC, Northern Trust Corp, Vanguard Group Inc., Algert Global LLC, Numeric Investors LLC, Spark Investment Management LLC and First Light Asset Management LLC. View Insider Buying and Selling for Veracyte.

Shares of Veracyte can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Veracyte stock can currently be purchased for approximately $8.48.